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Pyridazine-bridged cationic diiridium complexes as
potential dual-mode bioimaging probes†
Ruth E. Daniels,‡a Luke K. McKenzie,‡bc Jonathan R. Shewring, b Julia A. Weinstein,b
Valery N. Kozhevnikov *a and Helen E. Bryant *c
A novel diiridium complex [(N^C^N)2Ir(bis-N^C)Ir(N^C^N)2Cl]PF6 (N^C^N ¼ 2-[3-tert-butyl-5-(pyridin-2-
yl)phenyl]pyridine; bis-N^C ¼ 3,6-bis(4-tert-butylphenyl)pyridazine) was designed, synthesised and
characterised. The key feature of the complex is the bridging pyridazine ligand which brings two
cyclometallated Ir(III) metal centres close together so that Cl also acts as a bridging ligand leading to
a cationic complex. The ionic nature of the complex oﬀers a possibility of improving solubility in water.
The complex displays broad emission in the red region (lem ¼ 520–720 nm, s ¼ 1.89 ms, Fem ¼ 62% in
degassed acetonitrile). Cellular assays by multiphoton (lex ¼ 800 nm) and confocal (lex ¼ 405 nm)
microscopy demonstrate that the complex enters cells and localises to the mitochondria, demonstrating
cell permeability. Further, an appreciable yield of singlet oxygen generation (FD ¼ 0.45, direct method,
by 1O2 NIR emission in air equilibrated acetonitrile) suggests a possible future use in photodynamic
therapy. However, the complex has relatively high dark toxicity (LD50 ¼ 4.46 mM), which will likely hinder
its clinical application. Despite this toxicity, the broad emission spectrum of the complex and high
emission yield observed suggest a possible future use of this class of compound in emission bioimaging.
The presence of two heavy atoms also increases the scattering of electrons, supporting potential future
applications as a dual ﬂuorescence and electron microscopy probe.
1. Introduction
In comparison to traditional bio-imaging and photodynamic
therapy (PDT) agents, transition metal complexes combine
longer emission lifetimes and higher photo-stability, with
relative ease of chemical modication.1 During imaging,
longer emission lifetimes permit the use of time-gating to
reduce auto-uorescence and can be utilised to detect bio-
logically relevant analytes, such as O2 in vitro
1,2 and in vivo3,
while in PDT high emission lifetimes lead to high yields of 1O2
and/or other ROS, and thus eﬃcient photo-induced cell
killing. Increased photostability favours longer term tracking
during bio-imaging,4,5 and increases the photosensitizing
activity of an agent during PDT.
In the eld of transition metal complexes for use in bio-
imaging, ruthenium, rhenium and platinum complexes domi-
nated the early literature. However, iridium complexes with
high emission quantum yields and localisation to a wide variety
of sub-cellular organelles have seen a surge in popularity over
the last decade.6–11 In PDT, ruthenium complexes have domi-
nated the eld of transition metal photosensitizers12–16 with one
Ru(II) complex having entered clinical trials in Canada.17,18 In
comparison, iridium complexes in PDT are yet to be fully
explored. Importantly a few iridium complexes have been
recently shown to have photo-toxicities at low light doses under
both one-19–25 and two-photon excitation,26–30 suggesting that
Ir(III) containing complexes hold future potential for PDT.
Previously we reported several families of highly luminescent
transition metal (TM) complexes linked by cyclometallating
ditopic ligands.31–34 In comparison with their monometallic
analogues, these polynuclear complexes show red-shied
absorption and luminescence properties that may minimise
the background auto-uorescence in imaging of biological
objects. In addition, the appreciable molar extinction coeﬃ-
cient of the low-energy absorption band and high quantum
yields make them good imaging agents. The red-shi of the
absorption band is also advantageous for PDT because it allows
for excitation by wavelengths of light with greater tissue depth
penetration. The highest quantum yields we previously
observed with any of the complexes (up to 100%) were for the di-
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iridium(III) complexes formed by ditopic bis-N^C ligands in
conjunction with symmetrically-substituted terminal N^C^N
ligands.35 These complexes were also the easiest to synthesise
because the iridium centres are achiral and the formation of
diastereomers is not possible; the strong trans inuence of the
metallated rings of both the N^C^N and bis-N^C ligands directs
the relative positions of these ligands around the iridium
centres so that only one product is formed.35 The presence of
two closely positioned heavy atoms might also increase the
scattering of electrons suggesting the use of di-iridium
complexes as contrast reagents and thus combined with the
high quantum yields as dual-modality agents. However, all the
complexes prepared so far were designed for applications in
organic light emitting diodes and none are soluble in water.
Here, motivated by the advantages oﬀered by bimetallic Ir(III)
complexes, we sought to adapt the complexes by incorporating
pyridazine as a bridging heterocycle. The close proximity of Ir
atoms causes the Cl atom to act as a bridging ligand. Five
chelate rings form as a result, providing the driving force for the
reaction and leading to a rigid architecture. Another conse-
quence of the bridging Cl atom is that the complex becomes
ionic, which somewhat improves solubility in water. Once syn-
thesised, we characterised the complex and examined its ability
to enter cells, its sub-cellular localisation and its cellular
toxicity. In addition, it's use as a contrasting reagent in trans-
mission electron microscopy (TEM) was assessed.
2. Results and discussion
2.1. Synthesis
The terdentate proligand, 2-[3-tert-butyl-5-(pyridin-2-yl)phenyl]
pyridine (Ligand 1), was prepared using Stille cross-coupling
methodology (Fig. 1) and was isolated in good yield. Chou
et al. previously reported the synthesis of this terdentate ligand
via an alternative Suzuki–Miyaura cross-coupling route. The
inclusion of a tert-butyl substituent at the 5-position of the
Fig. 1 Synthesis of the terdentate proligand (Ligand 1) via a Stille
cross-coupling reaction.
Fig. 2 Synthesis of the bis-N^C coordinating bridging ligand (Ligand 2) via a Suzuki–Miyaura cross-coupling reaction.
Fig. 3 Synthesis of [(N^C^N)2Ir(bis-N^C)Ir(N^C^N)2Cl]PF6 (N^C^N ¼ 2-[3-tert-butyl-5-(pyridin-2-yl)phenyl]pyridine; bis-N^C ¼ 3,6-bis(4-
tert-butylphenyl)pyridazine) (complex-1) by reaction of dichloro-bridged iridium(III) dimer with the bis-bidentate proligand in toluene, using silver
triﬂate as a chloride scavenger.
Fig. 4 Changing bridging heterocycle from pyrimidine to pyridazine leads to cationic di-Ir complex (complex-1).
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 9670–9676 | 9671
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central phenyl ring ensures terdentate coordination to an iri-
dium(III) metal centre.36
The synthesis of the bis-N^C coordinating proligand, 3,6-
bis(4-tert-butylphenyl)pyridazine (Ligand 2), was achieved
through a Suzuki–Miyaura cross-coupling reaction between 3,6-
dichloropyridazine and 4-(tert-butyl)phenylboronic acid (Fig. 2).
The desired product was isolated in good yield. A similar
synthetic route for the preparation of 3,6-bis(4-tert-butylphenyl)
pyridazine was previously published by Wang and co-workers.37
The target dinuclear complex was prepared using a similar
synthetic method to that developed by Williams.35 Firstly, the
terdentate Ligand 1 was reacted with IrCl3$H2O at reux in
a mixture of 2-ethoxyethanol and water to give the dichloro-
bridged iridium dimer, [Ir(N^C^N)Cl(m-Cl)]2. in 85% yield. The
dimer was then reacted with the bis-bidentate proligand in
toluene, using silver triate as a chloride scavenger (Fig. 3).
Upon completion of the reaction, the mixture was treated with
excess HCl (3 M, aq.) in order to ensure that the only mono-
dentate ligand present on an iridium centre is chloride.
Following this, a Cl/PF6 anion exchange was carried out using
a saturated solution of KPF6(aq). Purication was carried out
using column chromatography to give the target complex 1
(Fig. 4), in 38% yield.35 The complex was characterised by 1H and
spectroscopy and high resolution mass spectrometry (ESI S3†).
2.2. Photophysical studies
In acetonitrile solution, 1 shows broad absorbtion in the UV/vis
region with appreciable absorption up to 500 nm. Upon
excitation (lexc¼ 400 nm) 1 shows broad emission (lem¼520–
720 nm). An emission lifetime of 1.9 ms and a quantum yield of
62% (11%) was measured in deaerated (by bubbling N2)
acetonitrile solution. Emission q.y. decreased 10-fold, to 5%,
in aerated solution indicating signicant quenching of the
emissive state by oxygen. The singlet oxygen yield, FD ¼ 0.45
was measured by direct detection of the 1O2 emission (1270 nm)
under UV excitation (lexc ¼ 355 nm). The appreciable singlet
oxygen yield showed the potential for this class of compounds
as therapeutic agents (Table 1 and ESI S1†).
2.3. Luminescent imaging and sub-cellular localisation
The complex is moderately soluble in water, DMSO was used to
assist solubilisation with the nal concentration of DMSO
always #2%.
Table 1 Summary of the photophysical data for 1
Compound lmax
a [nm] (3 [ dm3 mol1 cm1]) lem
a,b (max) s0, s1, s2
a,c [ns] F0, F1
a,b,d [%] FD
a,e [%]
1 235 (79 900), 284 (54 700), 397 (24 200) 576 1890, 226, 561/103 62, 5 45
a Acetonitrile. b lexc ¼ 400 nm.
c
s0 ¼ degassed acetonitrile, s1 ¼ acetonitrile, s2 ¼ water from DMSO stock.
d
F0 ¼ degassed, F1 ¼ aerated
[Ru(Bipy)3](PF6)2 standard.
e
lexc ¼ 355 nm, perinapthenone standard.
Fig. 5 Sub-cellular localisation of complex-1. HeLa cells following 5
hour incubation with 10 mM complex-1 (green), colocalised with (A)
Mitotracker orange (red) or (B) Lysotracker (red). Zoomed sections (9)
are shown as insets. Scale bars ¼ 20 mm.
Fig. 6 Complex-1 and Ligand 2 induce a signiﬁcant reduction in cell viability. Cell viability as measured by MTT assay after a 5 hour incubation
with (A). Complex-1 in HeLa and U2OS cells and (B). Ligands as indicated in HeLa cells. Mean and SEM of 4 independent repeats is shown.
Signiﬁcance calculated by Student's T-test compared to respective untreated control is indicated, where * ¼ p < 0.05 and ** ¼ p < 0.01.
9672 | RSC Adv., 2018, 8, 9670–9676 This journal is © The Royal Society of Chemistry 2018
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Emission microscopy of live cells incubated with 10 mM 1,
performed under multiphoton excitation (lexc ¼ 800 nm),
showed that 1 enters cells and localises in the cytoplasm with
distinct punctate staining (ESI S2†). These results are consistent
with those reported previously for cationic metal complexes,
which are known to locate in mitochondrial and lysosomal
structures.38 Co-localisation of 1 with mitochondria was
conrmed using organelle specic stains and confocal micros-
copy (lexc ¼ 405 nm) (Fig. 5A), giving a Pearson's correlation
coeﬃcient of R ¼ 0.76 (averaged over 15 cells) for mitotracker
red. Co-localisation of 1 with lysotracker red was not observed
(Fig. 5B) indicating that the punctate staining may result from
other endosomal structures (Pearson's correlation coeﬃcient of
R ¼ 0.53 with lysotracker red (averaged over 15 cells)).
2.4. Cellular toxicity
Following an incubation time of 5 hours to mimic imaging
conditions, 1 induced a signicant dose dependent reduction in
metabolic activity/cell viability in both U2OS and HeLa cancer
cell lines as indicated by MTT assay (Fig. 6A). The eﬀect of the
associated ligands was also measured. Ligand 1, did not reduce
cell viability whilst Ligand 2, induced a similar reduction in
metabolic activity as 1 (Fig. 6B). The MTT assay measures the
metabolic activity of a cell, and thus is considered a read out of
cell viability, however it is not a measure of long-term cell
survival. A clonogenic survival assay was used in order to obtain
an assessment of the cellular toxicity. In these assays, cells were
plated at low density prior to a 5 hour incubation with 1 or its
associated ligands, subsequently cells were le to recover and
form colonies for 10 days. In this more reliable assay of cell
toxicity 1 showed signicant toxicity (LD50 ¼ 4.46 mM) while the
associated ligands induced only slight toxicity at the highest
doses tested (LD50 $ 20 mM) (Fig. 7). Taken together the MTT
and clonogenic survival data reveal that while Ligand 2 tran-
siently eﬀects themetabolic activity of cells, over the short term 1
is signicantly more cytotoxic to cells than either of the ligands.
2.5. Transmission electron microscopy (TEM)
Dual-modality imaging agents have district advantages over
agents used in a single method, combining strengths of
Fig. 7 Complex-1 reduces cell survival to a signiﬁcantly greater
degree than each ligand alone. Long term survival (10 days) as
measured by clonogenic survival assay after a 5 hour incubation with
complex-1/Ligands as indicated in HeLa cells. Mean and SD of 2
independent repeats (each conducted in duplicate is shown). Signiﬁ-
cance calculated by Student's T-test compared to respective
untreated control is indicated, where * ¼ p < 0.05, ** ¼ p < 0.01 and
*** ¼ p < 0.001.
Fig. 8 Transmission Electron Microscopy images of HeLa cells using complex-1 as contrast agent. Cells incubated with or without 20 mM
complex-1 for 4 h, example images with and without standard contrast (“double contrasting”, with uranyl acetate and lead citrate). (A) Example
images of staining with complex-1 alone. (B) Example images of cells unstained, stained using standard double contrast agents and stained with
complex-1 plus standard agents. Scale bars ¼ 1 mm.
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 9670–9676 | 9673
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individual imaging techniques. The potential of 1 as a staining
agent in transmission electron microscopy (TEM) was evaluated
as follows. Live U2OS cells were incubated with 1 (20 mM, 4
hours), xed, processed for TEM in the presence or absence of
standard contrasting agents, and imaged (Fig. 8). Contrast in
the cells stained with 1 was enhanced compared to unstained
cells. Interestingly 1 also increased contrast in organelles other
than mitochondria, this raises the possibility that the micro-
environment in live cells means that luminescence is greater in
the mitochondria, alternatively the complex might leak and
diﬀuse around the cell while being prepped for TEM as we
didn't use any OsO4 which acts as a secondary xative. Impor-
tantly, 1 did not interfere with standard contrast enhancing
reagents (uranyl acetate and lead citrate).
3. Conclusion
We have demonstrated that a novel pyridazine-bridged cationic
di-iridium complex can enter live cells, has photo-physical
properties favourable for imaging applications, and generates
singlet oxygen in considerable yield. However, due to high dark
cytotoxicity, this complex is unlikely to be suitable for PDT
applications. Instead, the toxicity of the complex could be
exploited in other applications where its intrinsic toxicity could
be benecial, such as development of new anticancer agents.
The photophysical properties of the complexes are of interest
for luminescent bioimaging and the presence of two heavy
atoms allows its use as a contrast agent in TEM. Potentially, the
structure of the complex can be varied trough modication of
both bridging and auxiliary ligands as well as by employing
diﬀerent metals to ne-tune the properties and reduce toxicity.
4. Materials and methods/
experimental section
4.1. Synthesis and characterisation
4.1.1. Ligand 1.36 A mixture of 1,3-dibromo-5-(tert-butyl)
benzene (3.01 g, 10.3 mmol), 2-(tributylstannyl)pyridine (9.54 g,
25.7mmol) and tetrakis(triphenylphosphine)palladium (0.358 g,
0.309 mmol) were added to toluene (100 mL) and the reaction
mixture degassed for 15 min under argon. The reaction mixture
was heated to reux (140 C) for 20 h. The reaction mixture was
puried by column chromatography (silica gel, petroleum
ether : ethyl acetate 100 : 0 to 4 : 1 to 6 : 1 to 3 : 1) and a white
solid was obtained (2.11 g, 7.31 mmol, 71%). 1HNMR (400 MHz,
CDCl3): d 8.72 (d, 2H, J ¼ 1.6), 8.34 (d, 1H, J ¼ 1.4), 8.12 (d, 2H, J
¼ 1.4), 7.82 (d, 2H, J ¼ 7.8), 7.76 (t, 2H, J ¼ 7.8), 7.26–7.23 (m,
2H), 1.45 (s, 9H); 13CNMR (CDCl3, 100MHz): d 157.83 (C), 152.23
(C), 149.66 (CH), 139.71 (C), 136.67 (CH), 124.75 (CH), 123.02
(CH), 122.08 (CH), 120.93 (CH), 35.12 (C), 31.48 (C–(CH3)3).
4.1.2. Ligand 2.37 3,6-Dichloropyridazine (0.497 g, 3.33
mmol), (4-tert-butylphenyl)boronic acid (1.54 g, 8.67 mmol) and
a 2 M aqueous potassium carbonate solution (2.76 g,
20.0 mmol, 10.0 mL) were added to a round-bottomed ask. 1,4-
Dioxane (25 mL) was added. The mixture was degassed under
argon for 20 min. Tetrakis(triphenylphosphine)palladium
(0.231 g, 0.200 mmol) was added and the reaction mixture
degassed for a further 10 minutes. The reaction was heated to
95 C for 42 h. The reaction was cooled to room temperature. A
precipitate formed and this precipitate was ltered in vacuo. The
solid was then recrystallised from dimethylformamide to give
the product as a silver solid (0.659 g, 1.91 mmol, 57%). 1H NMR
(CDCl3, 400 MHz): d 8.11 (d, 4H, J ¼ 8.2), 7.90 (s, 2H), 7.57 (d,
4H, J¼ 8.2), 1.39 (s, 18H); 13C DEPT135 NMR (CDCl3, 400 MHz):
d 157.24 (C), 153.28 (C), 133.33 (C), 126.58 (C–H), 126.02 (CH),
123.86 (CH), 34.83 (C), 31.26 (C–(CH3)3).
4.1.3. 1
Step 1. A mixture of 1,3-di(2-pyridyl)-5-(tert-butyl)benzene
Ligand 1 (0.609 g, 2.08 mmol) and iridium chloride hydrate
(0.768 g, 2.08 mmol) were added to a 3 : 1 mixture of 2-ethox-
yethanol and water (100 mL). The reaction mixture was heated
to reux (bath temperature 130 C) for 24 h under argon and
then allowed to cool to room temperature. The resulting orange
solid was ltered oﬀ, washed with ethanol and water to give
intermediate dichlorobridged iridium complex (0.972 g,
1.77 mmol, 85%) which was used in the following step without
further purication.
Step 2. The dichlorobridged iridium complex from step 1
(0.170 g, 0.308 mmol) was added to a round-bottomed ask.
Toluene (30 mL) was added and the mixture stirred. Silver tri-
ate (0.122 g, 0.463 mmol) was added. 3,6-Bis(4-tert-butyl-
phenyl)pyridazine Ligand 2 (0.0531 g, 0.154 mmol) was added
and the reaction mixture was heated to reux for 15 h. The
reaction mixture was removed from the heat and 3 M hydro-
chloric acid solution (7 mL) was added. The mixture was stirred
for 5 min. The solvent was evaporated to dryness. A mixture of
1 : 1 acetonitrile : water (4 mL) was added to the residue. To the
solution formed, excess saturated aqueous ammonium hexa-
uorophosphate solution was added. An orange solid precipi-
tated and was ltered in vacuo to give the crude product (0.233 g,
0.174 mmol). The product was then puried by column chro-
matography (silica gel, DCM : EtOAc 10 : 1). Yellow solid
(0.0781 g, 0.0584mmol, 38%). 1HNMR (CDCl3, 400MHz): d 8.72
(s, 2H), 8.00 (d, 4H, J ¼ 5.0), 7.71 (dd, 6H, J ¼ 8.2, 3.2), 7.689 (s,
4H), 7.50 (td, 4H, J¼ 7.3, 1.8), 6.94–6.92 (m, 6H), 6.00 (d, 2H, J¼
1.8), 1.37 (s, 18H), 0.87 (s, 18H). HRMS (FTMS+) for [M]+ calcd.
1337.4129, found 1337.4144; for [M–(Ir(NCN))–Cl]+ calcd.
823.0780, found 823.3359.
4.2. Photophysical studies
The UV/vis spectra were recorded on Varian Cary 5000 UV-vis-
NIR spectrophotometer in 1 cm quartz cuvettes. The lumines-
cence spectra were recorded on Fluoromax 4 spectrouorimeter
(HORIBA Jobin Yvon). Emission lifetime measurements were
performed on the mini-s spectrouorometer (Edinburgh
Instruments), with 405 nm pulsed diode laser as an excitation
source. The emission decays were detected in the spectral range
475–525 nm selected by a bandpass lter.
4.3. Singlet oxygen yield
The singlet oxygen yield of the compound was measured by
direct detection of the singlet oxygen emissiton (lem¼ 1270 nm,
9674 | RSC Adv., 2018, 8, 9670–9676 This journal is © The Royal Society of Chemistry 2018
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detected with a cut-oﬀ >1100 nm lter) in aerated acetonitrile
against the standard perinapthenone with UV excitation (lex ¼
355 nm), according to the method previously described.26
4.4. Cell culture
Both cell lines HeLa (human cervical cancer) and U2OS (bone
osteosarcoma) were purchased from American Type Culture
Collection – LGC partnership (Teddington, UK). The cells were
cultured in Dulbecco's modied Eagles Medium (DMEM)
(Lonza, Cambridge UK) with 10% fetal calf serum (FCS) (Lonza,
Cambridge UK) and incubated at 37 C (5% CO2). Cells were
routinely checked for mycoplasma contamination.
4.5. Cell imaging
Cells were plated at 150 000 cells per well onto sterile coverslips
(22  22 mm). Following over night incubation, 10 or 20 mM
nal concentration of 1 (diluted from 1 mM stock solution in
DMSO) was added to cells, control wells were incubated with
equivalent DMSO concentration and plates were incubated for 5
hours. Following incubation, the cells were washed (3 X PBS)
and xed (4% paraformaldehyde in PBS, 20 min) before being
washed (3 X PBS) and mounted to microscope slides (immu-
mount, 20 min). For mitotracker red staining (MitoTracker™
Red CMXRos, Molecular Probes® by Life Technologies Ltd,
Paisley, UK) a nal staining concentration of 100 nM was added
to the cells in 30 min before washing, xing and mounting. For
lysotracker red staining (LysoTracker™ Red DND-99, Molecular
Probes® by Life Technologies Ltd, Paisley, UK) a nal staining
concentration of 75 nM was added for 1 hour before washing,
xing and mounting.
For the multiphoton imaging (Coherent Chameleon femto-
second pulsed laser, Inverted Zeiss LSM 510 NLO microscope)
800 nm was used to excite 1; emission was registered in the
region 565–615 nm For the co-localisation imaging a confocal
microscope was used (Nikon A1) with a 60  lens (CFI Plan
Apochromat VC 60 oil, NA 1.4). A diode laser (405 nm) was
used to excite 1 and a sapphire laser (561 nm) was used to excite
the co-stains. Pearson's correlation coeﬃcients were calculated
using the open source imaging soware Fiji (based on ImageJ)
and the coloc 2 colocalisation tool. The threshold regression
chosen was Bisection.
4.6. Proliferation assay – MTT
96-well plates were seeded with cells (HeLa or U2OS at 8000/
well) in culture media (DMEM with 10% FCS) and incubated
(37 C, 5% CO2, overnight). Treatment solutions were made up
in media (DMEM with 10% FCS) with the compound diluted
from a DMSO stock (1 mM) to the desired staining concentra-
tions (0, 5, 10 and 20 mM) with the nal concentration of DMSO
equal in all samples (2%)
4.7. Toxicity assay – clonogenic survival
6-well plates were seeded at low density (HeLa, 200 and 400 cells
per well) in culture medium (DMEM with 10% FCS) and incu-
bated (37 C, 5% CO2, overnight). Treatment solutions were
prepared as above and added (1mL per well, 5 hours). Following
incubation the treatment solution was removed and cells
washed (1 X PBS) and fresh media was added (2 mL per well).
The plates were le until visible cell colonies had formed.
Media was replaced with staining solution (4% methylene blue,
70% methanol, minimum 30 min). The staining solution was
washed oﬀ and colonies counted with each colony representing
a surviving cell.
4.8. Transmission electron microscopy
HeLa cells were cultured in T-25 asks as above until 90%
conuency is achieved. Media was then removed and the cells
washed with sterile PBS (5 mL) before incubation with 20 mM 1
for 4 h. 1 was the removed and the cells washed with sterile PBS
(2  5 mL). Cells were detached using Trypsin EDTA, washed in
media and glutaraldehyde (2.5% in cacodylate buﬀer) was
added to x the cells overnight at 4 C. Cells were then
dehydrated, embedded in Araldite and sectioned in to 85 nm
sections and mounted on copper grids before imaging under
TEM having either been unstained or stained with standard
contrast agent (OsO4 2%, 1 h, UAc2 3%, 25 min, Reynold's Lead
Citrate, 5 min). All TEM imaging was carried out using a FEI
tecnai 120Kv G2 Biotwin TEM with an Orius SC100 bottom
mounted camera using Gatan Digital Micrograph soware.
Image analysis was performed using imageJ.
Author contributions
VK, JW and HB conceived and designed the study, RD syn-
thesised and characterised all compounds, LM performed the
photo-physical analysis and toxicity assays, LM and JS per-
formed the imaging, RD, LM, JW, JS, VK and HB wrote the
manuscript.
Competing ﬁnancial interests
The authors declare no competing nancial interests.
Acknowledgements
This work was funded jointly by University of Sheﬃeld, North-
umbria University, Yorkshire Cancer Research, Cancer Research
UK, BBSRC, EPSRC KTA, MRC POC funds, Welcome Trust grant
WT093134AIA and MRC SHIMA award MR/K015753/1. The
authors would like to thank Dr D. Robinson for help in
capturing images.
References
1 E. Baggaley, S. W. Botchway, J. W. Haycock, H. Morris,
I. V. Sazanovich, J. A. G. Williams and J. A. Weinstein,
Chem. Sci., 2014, 5, 879–886.
2 A. Martin, A. Byrne, C. S. Burke, R. J. Forster and T. E. Keyes,
J. Am. Chem. Soc., 2014, 136, 15300–15309.
3 A. Parapaleix, Y. G. Houssen and S. Charpak, Nat. Med., 2013,
19, 241–246.
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 9670–9676 | 9675
Paper RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
6 
M
ar
ch
 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
7/
05
/2
01
8 
14
:2
7:
32
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
4 Y. Chen, L. Qiao, L. Ji and H. Chao, Biomaterials, 2014, 35, 2–
13.
5 K. Qui, H. Huang, B. Liu, Y. Liu, Z. Huang, Y. Chen, L. Ji and
H. Chao, ACS Appl. Mater. Interfaces, 2016, 8, 12702–12710.
6 E. Baggaley, J. A. Weinstein and J. A. G. Williams, Coord.
Chem. Rev., 2012, 256, 1762–1785.
7 Y. You, Curr. Opin. Chem. Biol., 2013, 17, 699–707.
8 K. Yina´Zhang, Chem. Comm., 2015, 51, 7943–7946.
9 K. Y. Zhang, S. P.-Y. Li, N. Zhu, I. W.-S. Or, M. S. H. Cheung,
Y.-W. Lam and K. K.-W. Lo, Inorg. Chem., 2010, 49, 2530–
2540.
10 T. F. Anjong, G. Kim, H. Y. Jang, J. Yoon and J. Kim, New J.
Chem., 2016, 41, 377–386.
11 C. Ho, K.-L. Wong, H.-K. Kong, Y.-M. Ho, C.-L. Chan,
W.-M. Kwok, K.-Y. Leung, H.-L. Tam, M.-W. Lam and
X.-F. Ren, Chem. Commun., 2012, 48, 2525–2527.
12 A. Frei, R. Rubbiani, S. Tubafard, O. Blacque, P. Anstaett,
A. Felgentra¨ger, T. Maisch, L. Spiccia and G. Gasser, J.
Med. Chem., 2014, 57, 7280–7292.
13 H. Huang, B. Yu, P. Zhang, J. Huang, Y. Chen, G. Gasser, L. Ji
and H. Chao, Angew. Chem., Int. Ed., 2015, 127, 14255–14258.
14 J. Hess, H. Huang, A. Kaiser, V. Pierroz, O. Blacque, H. Chao
and G. Gasser, Chem.–Eur. J., 2017, 23, 9888–9896.
15 C. Mari and G. Gasser, Chimia, 2015, 69, 176–181.
16 M. G. Walker, P. J. Jarman, M. R. Gill, X. Tian, H. Ahmad,
P. A. Reddy, L. McKenzie, J. A. Weinstein, A. Meijer and
G. Battaglia, Chem.–Eur. J., 2016, 22, 5996–6000.
17 J. Fong, K. Kasimova, Y. Arenas, P. Kaspler, S. Lazic,
A. Mandel and L. Lilge, Photochem. Photobiol. Sci., 2015,
14, 2014–2023.
18 S. Lazic, P. Kaspler, G. Shi, S. Monro, T. Sainuddin,
S. Forward, K. Kasimova, R. Hennigar, A. Mandel and
S. McFarland, Photochem. Photobiol., 2017, 93, 1248–1258.
19 Y. Li, C.-P. Tan, W. Zhang, L. He, L.-N. Ji and Z.-W. Mao,
Biomaterials, 2015, 39, 95–104.
20 C. Mari, H. Huang, R. Rubbiani, M. Schulze, F. Wu¨rthner,
H. Chao and G. Gasser, Eur. J. Inorg. Chem., 2016, 2017,
1745–1752.
21 S. P.-Y. Li, C. T.-S. Lau, M.-W. Louie, Y.-W. Lam, S. H. Cheng
and K. K.-W. Lo, Biomaterials, 2013, 34, 7519–7532.
22 L. He, Y. Li, C.-P. Tan, R.-R. Ye, M.-H. Chen, L.-N. Ji and
Z.-W. Mao, Chem. Sci., 2015, 6, 5409–5418.
23 R.-R. Ye, C.-P. Tan, L. He, M.-H. Chen, L.-N. Ji and Z.-W. Mao,
Chem. Commun., 2014, 50, 10945–10948.
24 F. Xue, Y. Lu, Z. Zhou, M. Shi, Y. Yan, H. Yang and S. Yang,
Organometallics, 2014, 34, 73–77.
25 D. Maggioni, M. Galli, L. D'Alfonso, D. Inverso, M. V. Dozzi,
L. Sironi, M. Lannacone, M. Collini, P. Ferruti and
E. Ranucci, Inorg. Chem., 2015, 54, 544–553.
26 L. K. McKenzie, I. V. Sazanovich, E. Baggaley, M. Bonneau,
V. Guerchais, J. A. G. Williams, J. A. Weinstein and
H. E. Bryant, Chem.–Eur. J., 2017, 23, 234–238.
27 X. Tian, Y. Zhu, M. Zhang, L. Luo, J. Wu, H. Zhou, L. Guan,
G. Battaglia and Y. Tian, Chem. Commun., 2017, 53, 3303–
3306.
28 J. Liu, C. Jin, B. Yuan, X. Liu, Y. Chen, L. Ji and H. Chao,
Chem. Commun., 2017, 53, 2052–2055.
29 J. S. Nam, M.-G. Kang, J. Kang, S.-Y. Park, S. J. C. Lee,
H.-T. Kim, J. K. Seo, O.-H. Kwon, M. H. Lim and
H.-W. Rhee, J. Am. Chem. Soc., 2016, 138, 10968–10977.
30 E. M. Boreham, L. Jones, A. N. Swinburne, M. Blanchard-
Desce, V. Hugues, C. Terryn, F. Miomandre, G. Lemercier
and L. S. Natrajan, Dalton Trans., 2015, 44, 16127–16135.
31 V. N. Kozhevnikov, M. C. Durrant and J. A. G. Williams, Inorg.
Chem., 2011, 50, 6304–6313.
32 S. Culham, P.-H. Lanoe¨, V. L. Whittle, M. C. Durrant,
J. A. G. Williams and V. N. Kozhevnikov, Inorg. Chem.,
2013, 52, 10992–11003.
33 P.-H. Lanoe¨, C. M. Tong, R. W. Harrington, M. R. Probert,
W. Clegg, J. A. G. Williams and V. N. Kozhevnikov, Chem.
Commun., 2014, 50, 6831–6834.
34 G. Turnbull, J. A. G. Williams and V. N. Kozhevnikov, Chem.
Commun., 2017, 53, 2729–2732.
35 R. E. Daniels, S. Culham, M. Hunter, M. C. Durrant,
M. R. Probert, W. Clegg, J. A. G. Williams and
V. N. Kozhevnikov, Dalton Trans., 2016, 45, 6949–6962.
36 B. Tong, H.-Y. Ku, I. J. Chen, Y. Chi, H.-C. Kao, C.-C. Yeh,
C.-H. Chang, S.-H. Liu, G.-H. Lee and P.-T. Chou, J. Mater.
Chem. C, 2015, 3, 3460–3471.
37 W. Wang, W. Meng and H. Du, Dalton Trans., 2016, 45, 5945–
5948.
38 L. K. McKenzie, I. V. Sazanovich, E. Baggaley, M. Bonneau,
V. Guerchais, J. A. G. Williams, J. A. Weinstein and
H. E. Bryant, Chem.–Eur. J., 2017, 23, 234–238.
9676 | RSC Adv., 2018, 8, 9670–9676 This journal is © The Royal Society of Chemistry 2018
RSC Advances Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
6 
M
ar
ch
 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
7/
05
/2
01
8 
14
:2
7:
32
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
